All In Biotech

NDA 020626 · Glaxosmithkline

Imitrex

Sumatriptan · Nasal · Serotonin-1b and Serotonin-1d Receptor Agonist

Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Aug 26, 1997

Approved uses

2

Original approval plus efficacy supplements

Registered trials

113

33 Phase 3, 5 recruiting

FAERS reports

38,243

19,164 serious, 909 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 29, 2026.

Sumatriptan Nasal Spray is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with Sumatriptan Nasal Spray, reconsider the diagnosis of migraine before Sumatriptan Nasal Spray is administered to treat any subsequent attacks. • Sumatriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of Sumatriptan Nasal Spray have not been established for cluster headache. Sumatriptan is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use: • Use only if a clear diagnosis of migraine headache has been established. ( 1 ) • Not indicated for the prophylactic therapy of migraine attacks. ( 1 ) • Not indicated for the treatment of cluster headache. ( 1 )

Mechanism: Sumatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5‑HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • IMITREX · SUMATRIPTAN 10MG/SPRAY · SPRAY, NASAL · Discontinued
  • IMITREX · SUMATRIPTAN 20MG/SPRAY · SPRAY, NASAL · Prescription · TE AB
  • IMITREX · SUMATRIPTAN 5MG/SPRAY · SPRAY, NASAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sumatriptan" as an intervention, any sponsor and status, largest first.

All 113 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,506
  • headache3,209
  • nausea2,893
  • migraine2,820
  • fatigue2,169
  • pain2,016
  • dizziness1,727
  • vomiting1,649
  • dyspnoea1,384
  • off label use1,332
  • anxiety1,310
  • diarrhoea1,242

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004893
20051,256
2006842
2007851
2008792
2009865
2010798
2011904
20121,153
20131,087
20141,410
20152,197
20162,977
20172,171
20182,645
20193,028
20202,670
20212,165
20222,176
20232,174
20241,888
20251,858
20261,440

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Imitrex (Sumatriptan)

2024 spending

$28K

Beneficiaries

24

36 claims

Per beneficiary

$1,184

$92.91 per unit

View as table
YearSpending
2020$283,044
2021$221,580
2022$174,491
2023$232,297
2024$28,424

Part D: Imitrex* (Sumatriptan Succinate)

2024 spending

$5.1M

Beneficiaries

803

3,210 claims

Per beneficiary

$6,396

$169.56 per unit

View as table
YearSpending
2020$6,791,519
2021$6,164,539
2022$5,295,110
2023$5,133,446
2024$5,135,591

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 589 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.